Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites

TL;DR

This paper explores potential ligand binding sites on HIV integrase to aid in the development of new inhibitors, focusing on docking studies of known drugs like Raltegravir and Elvitegravir.

Contribution

It identifies and analyzes potential binding sites on HIV integrase for designing novel inhibitors using docking techniques.

Findings

Potential binding sites identified on HIV integrase.

Docking studies confirm binding affinity of Raltegravir and Elvitegravir.

Insights for designing new anti-HIV drugs.

Abstract

HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.